Alkeon Capital Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX

Avoro Capital Advisors LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:

RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nas

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) have been given an average

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $1.12 per share, beating the Zac

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.06 per share which beat the analyst

BioCryst Pharma (NASDAQ:BCRX) reported quarterly sales of $163.284 million which beat the analyst co

—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European O

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings bea

GSA Capital Partners LLP lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 70.

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abs

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) has earned an average rating of "Mod

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - G

Campbell and CO Investment Adviser LLC lessened its position in shares of BioCryst Pharmaceuticals,

BioCryst Pharmaceuticals (NASDAQ: BCRX) outlined a multi-pronged growth strategy at the JPMorgan Hea

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Tran

BioCryst Pharma (NASDAQ:BCRX) sees FY2026 sales of $635.000 million-$660.000 million vs $657.200 mil

–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue w

HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy

BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to childre

–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and old

 Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on

Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperfo

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:BCRX) with a Equal-Weight and lowers

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the

Retail investors are preparing for another busy week of earnings season with more than 1,600 compani

BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abs

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Ou

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with naveniba

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and s

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $

Financial Outlook for 2025The company is maintaining its outlook for full year 2025 global net ORLAD

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.02 per share which missed the analys